Inventiva (IVA) Q2 2026 Earnings Call Transcript
Lanifibranor Phase III results expected Q4 2026, potential FDA submission H1 2027.
Overview
Image source: The Motley Fool.
Sept. 28, 2026
Details
Need a quote from a Motley Fool analyst? Email [email protected]
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.